Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 10 Nov 2021
SMC accepts oral therapy for relapsing multiple sclerosis
10 November 2021 - Janssen has announced that the SMC have accepted Ponvory (ponesimod) within NHS Scotland, as a treatment for ...
Posted by Michael Wonder on 10 Nov 2021
EMA starts evaluating use of COVID-19 vaccine Spikevax in children aged 6 to 11
10 November 2021 - EMA has started evaluating an application to extend the use of Moderna’s COVID-19 vaccine, Spikevax, to ...
Posted by Michael Wonder on 10 Nov 2021
Universal health care is a fundamental right — being delusional is not
10 November 2021 - Singapore’s Health Ministry has announced that its citizens who choose not to be vaccinated will be ...
Posted by Michael Wonder on 10 Nov 2021
Health Canada authorises the use of the Pfizer-BioNTech Comirnaty COVID-19 vaccine as a booster shot
9 November 2021 - Health Canada has authorized the use of the Pfizer-BioNTech Comirnaty COVID-19 vaccine as a booster shot. ...
Posted by Michael Wonder on 10 Nov 2021
Moderna's COVID-19 vaccine (Spikevax) - provisional determination granted for proposed use in children and booster shot for adults under evaluation
10 November 2021 - The TGA has granted a provisional determination to Moderna in relation to its COVID-19 vaccine, Spikevax. ...
Posted by Michael Wonder on 09 Nov 2021
Australia to wait for data from US children before clearing vaccine here
10 November 2021 - Australia’s top immunisation advisers will wait on safety data from at least several hundred thousand young ...
Posted by Michael Wonder on 09 Nov 2021
WHO warns of massive syringe shortfall in 2022
10 November 2021 - There could be a shortage of up to two billion syringes in 2022 with billions more than ...
Posted by Michael Wonder on 09 Nov 2021
Merck and Ridgeback announce U.S. Government to purchase 1.4 million additional courses of molnupiravir, an investigational oral anti-viral medicine, for the treatment of mild to moderate COVID-19 in at risk adults
9 November 2021 - Merck and Ridgeback Biotherapeutics today announced that the United States Government will exercise two of its options ...
Posted by Michael Wonder on 09 Nov 2021
ICER releases draft evidence report on tirzepatide for type 2 diabetes mellitus
9 November 2021 - Public comment period now open until 8 December 2021; requests to make oral comment during public ...
Posted by Michael Wonder on 09 Nov 2021
FDA’s Woodcock says agency has resumed normal review pace for biosimilars, generics
9 November 2021 - Janet Woodcock, MD, acting commissioner of the FDA, delivered an upbeat report on biosimilars and generics progress ...
Posted by Michael Wonder on 09 Nov 2021
Moderna files to expand the conditional marketing authorisation for its COVID-19 vaccine in the European Union to include children ages 6-11 years
9 November 2021 - Submission based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11. ...
Posted by Michael Wonder on 09 Nov 2021
BerGenBio receives FDA fast track designation for bemcentinib in STK11 mutated advanced/metastatic non-small-cell lung cancer
9 November 2021 - BerGenBio today announces that the U.S. FDA has granted fast track designation for bemcentinib in combination with ...
Posted by Michael Wonder on 09 Nov 2021
Plus Therapeutics receives FDA fast track designation for 186RNL targeted radiotherapeutic for leptomeningeal metastases
9 November 2021 - Plus Therapeutics today announced that the U.S. FDA has granted the Company fast track designation for ...
Posted by Michael Wonder on 09 Nov 2021
A toxic drug price deal
8 November 2021 - The latest version of government price controls is barely better than the first. ...
Posted by Michael Wonder on 09 Nov 2021
TGA grants provisional determination to AstraZeneca for COVID-19 preventative treatment, tixagevimab and cilgavimab (Evusheld)
9 November 2021 - On 4 November 2021, the TGA granted provisional determination to AstraZeneca in relation to the COVID-19 treatment ...